Search Results - "Moules, I K"

Improved symptom relief and duodenal ulcer healing with lansoprazole, a new proton pump inhibitor, compared with ranitidine by Hawkey, C J, Long, R G, Bardhan, K D, Wormsley, K G, Cochran, K M, Christian, J, Moules, I K

“…The purpose of this study was to compare duodenal ulcer healing, symptom relief, and safety of lansoprazole (a new proton pump inhibitor) given at doses of 30…”
Get full text

Rapid healing of gastric ulcers with lansoprazole by Bardhan, K D, Ahlberg, J, Hislop, W S, Lindholmer, C, Long, R G, Morgan, A G, Sjostedt, S, Smith, P M, Stig, R, Wormsley, K G

“…Lansoprazole is a new proton pump inhibitor which powerfully decreases acid secretion. We compared the efficacy and short-term safety of lansoprazole against…”
Get more information

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial by Dormandy, John A, Charbonnel, Bernard, Eckland, David JA, Erdmann, Erland, Massi-Benedetti, Massimo, Moules, Ian K, Skene, Allan M, Tan, Meng H, Lefèbvre, Pierre J, Murray, Gordon D, Standl, Eberhard, Wilcox, Robert G, Wilhelmsen, Lars, Betteridge, John, Birkeland, Kåre, Golay, Alain, Heine, Robert J, Korányi, László, Laakso, Markku, Mokáň, Marián, Norkus, Antanas, Pirags, Valdis, Podar, Toomas, Scheen, André, Scherbaum, Werner, Schernthaner, Guntram, Schmitz, Ole, Škrha, Jan, Smith, Ulf, Tatoň, Jan

“…Patients with type 2 diabetes are at high risk of fatal and non-fatal myocardial infarction and stroke. There is indirect evidence that agonists of peroxisome…”
Get full text

Binding of amphipathic drugs and probes to biological membranes by Moules, I.K., Rooney, E.K., Lee, A.G.

“…The authors report ESR and fluorescence studies which suggest that amphipathic molecules can bind to the hydrophobic phase of typical biological membranes such…”
Get full text

Lansoprazole: pharmacokinetics and pharmacodynamics by Moules, I K

Get more information

Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. UK Lansoprazole Clinical Research Group by Bardhan, K D, Hawkey, C J, Long, R G, Morgan, A G, Wormsley, K G, Moules, I K, Brocklebank, D

“…Lansoprazole is a H+.K(+)-ATPase (proton pump) inhibitor with an anti-secretory action and is therefore potentially useful in the treatment of…”
Get more information